AstraZeneca says it has responded to the FDA's queries regarding Brilinta, its oral antiplatelet treatment for acute coronary syndromes, and believes its marketing application in the USA will be approved. The FDA (Food and Drug Administration) had requested further data on Brilinta's intraction with high-dose aspirin...
Read from Source
|
